YAP1 and neoplasm: On the other hand, the prostate cancer line LNCaP, which displayed negligible levels of YAP1 (Fig. S3I), was not significantly inhibited by the TONDU peptide (Fig. 2K), even at higher concentrations, thereby revealing specificity of the TONDU peptide to inhibit YAP-mediated tumor growth and presumably low off-target toxicity.